• WSJ

    • <h4>WSJ on Facebook</h4><div style="border: none; padding: 2px 3px;" class="fb-like" data-href="http://www.facebook.com/wsj" data-send="false" data-layout="button_count" data-width="250" data-show-faces="false" data-action="recommend"></div>
    • <h4>WSJ on Twitter</h4><a href="https://twitter.com/wsj" class="twitter-follow-button" data-show-count="true">Follow @wsj</a>
  • WSJ LIVE

    • WSJ Live on Facebook

    • WSJ Live on Twitter

  • MARKETWATCH

    • MarketWatch on Facebook

    • MarketWatch on Twitter

  • BARRON'S

    • Barron's on Facebook

    • Barron's on Twitter

  • Portfolio

    • Portfolio on Facebook

    • Portfolio on Twitter

  • DJX

    • Product X on Facebook

    • Product X on Twitter

    • RT
    • F
    • R&C
    • PE&VC
    • WSJ
    • B
  • MORE

    • WSJ Secure
    • BigCharts
    • DJX
    • Portfolio
    • WSJ Live
    • Financial News
    • Professor Journal
    • Student Journal
    • Virtual Stock Exchange
    • WSJ Classifieds
    • WSJ Classrooms
    • WSJ Radio
    • WSJ Wine
The Wall Street Journal
Menu
  • Home
  • World
  • U.S.
  • Business
  • Tech
  • Markets
  • Market Data
  • Your Money
  • Opinion
  • Life & Culture
  • N.Y.
  • Real Estate
  • Management

Also in WSJ.com:

  • Latest News
  • Today's Paper
  • Most Popular
  • Streams (TBD)
  • Video
  • Blogs

International Editions

  • U.S.
  • Asia
  • Europe
  • América Latina
  • Brasil
  • 中文-简体(China)
  • Deutschland
  • India
  • Indonesia
  • 日本(Japan)
  • 한국(Korea)
  • Türkiye
Market Data
  • Log In
  • Subscribe

Abbott Laboratories ABT (U.S.: NYSE)

View All companies
  • AT CLOSE 4:00 PM ET 09/12/14
  • $42.55 USD
  • -0.01 -0.02%
  • Volume 4,160,140
  • AFTER HOURS 6:15 PM ET 09/12/14
  • $42.56 0.01 0.02%
  • AFTER HOURS Vol 100,378
  • Volume 4,160,140
  • 65 Day Avg Vol 4,941,024
  • 1 Day Range 42.4506 - 42.87
  • 52 Week Range 32.75 - 43.27 (10/09/13 - 07/23/14)
  • 1 Day
  • 5 Day
  • 1 Month
  • 3 Month
  • YTD
  • 1 Year
  • 3 Year
  • $
  • %
Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care
  • Compare to
  • Today's Open 42.62
  • Prior Day Close 42.56 (09/11/14)
  • Performance Today
  • ABT -0.02%
  • DJIA -0.36%
  • S&P 500 -0.60%
  • Health Care -0.77%
Company Overview

Latest News Abbott Laboratories(ABT)

    • 09/11/14
    • The Wall Street Journal
    Abbott Labs Sets $3 Billion Buyback
    • The Wall Street Journal
    • 09/11/14
    • Press Release
    Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend
    • Press Release
    • 09/11/14
    • Press Release
    Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI)
    • Press Release
    • 09/08/14
    • WSJ Blogs
    FTC Sues Drug Makers Over Pay-To-Delay Deals
    • WSJ Blogs
    • 09/08/14
    • Press Release
    New Abbott Technology May Uncover the Root of Critical Infections and Cut Health Care Costs
    • Press Release
    • 09/03/14
    • Press Release
    Abbott Receives CE Mark for FreeStyle(R) Libre, a Revolutionary Glucose Monitoring System for People with Diabetes
    • Press Release
    • 09/03/14
    • Press Release
    Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
    • Press Release
    • 08/12/14
    • Press Release
    Access to Abbott's MitraClip(R) System Expands in the U.S. with Medicare National Coverage Determination
    • Press Release
    • 08/11/14
    • WSJ Blogs
    Merck KGaA is Fined by Brazil for Conspiring to Thwart Generic Drugs
    • WSJ Blogs
    • 08/07/14
    • Press Release
    New Product Launch, New Board Member, Major Contracts, Successful Testing, and Grants - Research Reports on Abbott, Illumina, General Dynamics, Raytheon and Northrop Grumman
    • Press Release
    • 07/31/14
    • WSJ Blogs
    Stewart, Colbert Take on Tax Inversions
    • WSJ Blogs
    • 07/31/14
    • WSJ Blogs
    After Spurning a U.S. Inversion, Meda Buys in Europe
    • WSJ Blogs
    • 07/28/14
    • Press Release
    Abbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association for Clinical Chemistry Lab Expo
    • Press Release
    • 07/25/14
    • The Wall Street Journal
    Humira Sales Lift AbbVie Profit
    • The Wall Street Journal
    • 07/24/14
    • Press Release
    Abbott Introduces New Similac(R) Breastfeeding Supplement with DHA, Lutein and Vitamin E
    • Press Release
    • 07/21/14
    • Press Release
    Health Care Equipment Equities Technical Notes -- Medtronic, Abbott Laboratories, Stryker, Zimmer Holdings, and EnteroMedics
    • Press Release
    • 07/18/14
    • The Wall Street Journal
    AbbVie to Buy Shire for $54 Billion
    • The Wall Street Journal
    • 07/18/14
    • Barron's
    AbbVie's $55 Billion Deal To Buy Shire Is Worth It
    • Barron's
    • 07/17/14
    • The Wall Street Journal
    Ignoring the Facts on Corporate Inversions
    • The Wall Street Journal
    • 07/17/14
    • WSJ Blogs
    Pharmalot, Pharmalittle: We're Reading About Sanofi, Roche and Lots More!
    • WSJ Blogs
    • 07/16/14
    • The Wall Street Journal
    Sanofi Looking At Options for Older Drug Lines
    • The Wall Street Journal
    • 07/16/14
    • WSJ Blogs
    Stocks to Watch: Time Warner, Bank of America, Intel
    • WSJ Blogs
    • 07/16/14
    • Dow Jones Newswires
    U.S. Hot Stocks: Hot Stocks to Watch
    • Dow Jones Newswires
    • 07/16/14
    • The Wall Street Journal
    Abbott Profit Falls Slightly
    • The Wall Street Journal
    • 07/16/14
    • WSJ Blogs
    Dealpolitik: Mylan's Simpler Inversion Structure Could Set Trend
    • WSJ Blogs
    • 07/16/14
    • Press Release
    Abbott Reports Second-Quarter 2014 Results
    • Press Release
    • 07/16/14
    • WSJ Blogs
    Morning MoneyBeat: What the Fed Really Thinks About the Markets
    • WSJ Blogs
    • 07/15/14
    • WSJ Blogs
    Obama Inversion Crackdown Could Snag Pending Deals
    • WSJ Blogs
    • 07/15/14
    • The Wall Street Journal
    The 10-Point: Gerard Baker on Inversion Tax Deals, Israel Cease-Fire, Pimco Tumult and More
    • The Wall Street Journal
    • 07/14/14
    • The Wall Street Journal
    Race to Cut Taxes Fuels Urge to Merge
    • The Wall Street Journal
    • 07/14/14
    • The Wall Street Journal
    U.S. Stands to Lose Billions From Corporate-Tax Inversions
    • The Wall Street Journal
    • 07/14/14
    • Press Release
    (CNW) Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
    • Press Release
    • 07/14/14
    • Press Release
    Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
    • Press Release
    • 07/14/14
    • Press Release
    Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction
    • Press Release
    • 07/14/14
    • Press Release
    (PR) Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
    • Press Release
    • 07/10/14
    • Press Release
    (CNW) Abbott Builds Long-Term Commitment in China
    • Press Release
    • 07/10/14
    • Press Release
    Abbott Builds Long-Term Commitment in China
    • Press Release
    • 07/10/14
    • Press Release
    (PR) Abbott Builds Long-Term Commitment in China
    • Press Release
    • 07/10/14
    • Press Release
    (CNW) Abbott and Fonterra to Form Strategic Alliance for Dairy Farming in China
    • Press Release
    • 07/10/14
    • Press Release
    (PR) Abbott and Fonterra to Form Strategic Alliance for Dairy Farming in China
    • Press Release
load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    27.46 (09/12/2014)
  • EPS (TTM)
    $1.55
  • Market Cap
    $64.00 B
  • Shares Outstanding
    1.50 B
  • Public Float
    1.50 B
  • Yield
    2.07% (09/12/2014)
  • Latest Dividend
    $0.22 (11/15/2014)
  • Ex-Dividend Date
    10/10/2014
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest

  • Shares Sold Short
    12.30 M (08/29/2014)
  • Change from Last
    +4.00%
  • Percent of Float
    0.82%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    1.12
    Net Money Flow ($)
    +2.04 M

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors (ABT)

Company Change P/E (TTM)
JNJ

Johnson & Johnson

+0.03% +0.03 18.98
PFE

Pfizer Inc.

-0.67% -0.20 18.24
RHHVF

Roche Holding AG Part. Cert.

-0.42% -1.25 21.24
NVS

Novartis AG ADS

-0.64% -0.60 22.87
GSK

GlaxoSmithKline PLC ADS

+0.28% +0.13 14.60
BMY

Bristol-Myers Squibb Co.

-0.83% -0.42 30.83
MYL

Mylan Inc.

-1.53% -0.73 30.46
AZNCF

Astrazeneca PLC

+0.20% +0.15 45.97
  • Competitor Data Provided By: capital cube

Profile (ABT)

Abbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products. The company operates through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products...

100 Abbott Park Road
Abbott Park Illinois 60064
United States

  • Website
  • Map
  • Employees 69,000
    Sector Pharmaceuticals
  • Sales or Revenue 21.85 B
    Industry Health Care
  • 1Y Sales Change -45.21%
    Fiscal Year Ends December 31 Download Reports
  • Miles D. White Chairman & Chief Executive Officer
  • Thomas C. Freyman Chief Financial Officer & Executive Vice President
  • Preston T. Simons Vice President-Information Technology
  • Kathryn S. Collins Vice President, Chief Ethics & Compliance Officer
  • More

Research & Ratings Abbott Laboratories(ABT)

Per-Share Earnings, Actuals and Estimates

ABT will report FY 2014 earnings on 01/21/2015 ABT will report Q3 earnings on 10/15/2014
  • Quarterly
  • Annual
Actual Analyst Range Consensus
0.80 0.60 0.40 0.20 0.00
Actual 0.55
0.51
Actual 0.58
0.58
Actual 0.41
0.35
Actual 0.54
0.51
0.59
0.70
Q32013 Q4 Q12014 Q2 Q3 Q4
4 3 2 1 0
Actual 1.62
2.02
2.23
2.47
2.76
FY 2013 FY 2014 FY 2015 FY 2016
Q3 2014 Estimate Trends
Current: $0.59
1 month ago: $0.59
3 months ago: $0.60
Q4 2014 Estimate Trends
Current: $0.70
1 month ago: $0.70
3 months ago: $0.69
FY 2014 Estimate Trends
Current: $2.23
1 month ago: $2.24
3 months ago: $2.20
FY 2015 Estimate Trends
Current: $2.47
1 month ago: $2.47
3 months ago: $2.45
  • More

Financials Abbott Laboratories(ABT)

  • Quarterly
  • Annual

Net Income

0 300M 600M 900M 1.2B
Jun 2013 Sep 2013 Dec 2013 Mar 2014 Jun 2014
0 2B 4B 6B
'09 '10 '11 '12 '13
Jun 2014 5-quarter trend
Net Income Growth -3.37%
Sales or Revenue 5.55 B
Sales or Revenue Growth +1.93%
EBITDA +1.21 B
2013 5-year trend
Net Income Growth -60.04%
Sales or Revenue 21.85 B
Sales or Revenue Growth -45.21%
EBITDA +4.38 B
  • More

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only. U.S. stock quote data and real-time U.S. stock indexes provided by Dow Jones.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

Bond quotes are updated in real-time. Source: Tullett Prebon PLC, ICAP PLC.

Currency quotes are updated in real-time. Source: ICAP PLC.

Advertisement
  • Wall Street Journal
  • Facebook
  • Twitter
  • LinkedIn
  • FourSquare
  • Google+
  • YouTube
  • Podcasts
  • RSS Feed
  • AppStore
  • Subscribe
  • /Login
  • Back to Top«
  • Customer Service

  • Customer Center
  • Contact Us
  • WSJ Weekend
  • Contact Directory
  • Corrections
  • Policy

  • Privacy Policy
  • Cookie Policy
  • Data Policy
  • Copyright Policy
  • Updated :  Subscriber Agreement
    & Terms of Use
  • Your Ad Choices
  • Ads

  • Advertise
  • Place a Classified Ad
  • Sell Your Home
  • Sell Your Business
  • Commercial Real Estate Ads
  • Recruitment & Career Ads
  • Franchising
  • Advertise Locally
  • Tools & Features

  • Apps
  • Emails & Alerts
  • Graphics & Photos
  • Columns
  • Topics
  • Guides
  • Portfolio
  • Old Portfolio
  • More

  • Register for Free
  • Reprints
  • Content Partnerships
  • Conferences
  • Mobile Site
  • News Archive
  • Jobs at WSJ
  • Copyright ©2014 Dow Jones & Company, Inc. All Rights Reserved.